Foundation Medicine and Relay Therapeutics Collaborate to Develop FoundationOne®CDx as a Companion Diagnostic for Relay’s Investigational FGFR2 Inhibitor, RLY-4008
September 12, 2022 06:30 AM Eastern Daylight Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Today Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, and Relay Therapeutics (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the...